Evidence map›Paper›PMID 25237624›Full record

ReviewWorld journal of methodology2013

Bone marrow cell-based regenerative therapy for liver cirrhosis.

Takafumi Saito, Kyoko Tomita, Hiroaki Haga, Kazuo Okumoto, Yoshiyuki Ueno

Abstract readReview
In one paragraph

Review in World journal of methodology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Current Understanding of Stem Cell and Secretome Therapies in Liver Diseases.Tissue engineering and regenerative medicine · 2017
    Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Takafumi SaitoTakafumi Saito, Kyoko Tomita, Hiroaki Haga, Kazuo Okumoto, Yoshiyuki Ueno, Department of Gastroenterology, Yamagata University School of Medicine, Yamagata 990-9585, Japan.
Kyoko TomitaTakafumi Saito, Kyoko Tomita, Hiroaki Haga, Kazuo Okumoto, Yoshiyuki Ueno, Department of Gastroenterology, Yamagata University School of Medicine, Yamagata 990-9585, Japan.
Hiroaki HagaTakafumi Saito, Kyoko Tomita, Hiroaki Haga, Kazuo Okumoto, Yoshiyuki Ueno, Department of Gastroenterology, Yamagata University School of Medicine, Yamagata 990-9585, Japan.
Kazuo OkumotoTakafumi Saito, Kyoko Tomita, Hiroaki Haga, Kazuo Okumoto, Yoshiyuki Ueno, Department of Gastroenterology, Yamagata University School of Medicine, Yamagata 990-9585, Japan.
Yoshiyuki UenoTakafumi Saito, Kyoko Tomita, Hiroaki Haga, Kazuo Okumoto, Yoshiyuki Ueno, Department of Gastroenterology, Yamagata University School of Medicine, Yamagata 990-9585, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bone marrow cells are capable of differentiation into liver cells. Therefore, transplantation of bone marrow cells has considerable potential as a future therapy for regeneration of damaged liver tissue. Autologous bone marrow infusion therapy has been applied to patients with liver cirrhosis, and improvement of liver function parameters has been demonstrated. In this review, we summarize clinical trials of regenerative therapy using bone marrow cells for advanced liver diseases including cirrhosis, as well as topics pertaining to basic in vitro or in vivo approaches in order to outline the essentials of this novel treatment modality.

Indexed as

Bone marrowCirrhosisLiver regenerationStem cellTransplantation

Identifiers

PMID25237624
PMCPMC4145572

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.